CRISPR 기반 POC 진단 시장 규모, 점유율 및 동향 분석 리포트 : 제품별, 기술별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

CRISPR-based POC Diagnostics Market Summary

The global CRISPR-based POC diagnostics market size was estimated at USD 502.64 million in 2024 and is projected to reach USD 1,786.56 million by 2033, growing at a CAGR of 15.41% from 2025 to 2033. The market is expanding as diagnostic capabilities shift closer to the point of care, supported by broader availability of testing in regions with limited healthcare infrastructure.

Cost-effectiveness, high accuracy, and ease of use propel adoption across healthcare systems globally. Strategic partnerships are bringing innovations into the market, specifically in underserved settings. For instance, in August 2023, Crisprbits partnered with Molbio Diagnostics Limited to launch CRISPR-based point-of-care tests to provide cost-effective, innovative, and highly accurate diagnostic solutions while expanding market opportunities and transforming point-of-care diagnostics.

Furthermore, the increasing prevalence of infectious diseases is a major factor propelling the growth of the market. The global burden of infectious conditions such as influenza, tuberculosis, viral hepatitis, and sexually transmitted infections (STIs) has risen steadily, creating an urgent need for rapid, accurate, and affordable diagnostic solutions. In February 2025, the WHO noted that seasonal influenza continues to pose a significant global health burden, with an estimated one billion cases reported annually, including 3-5 million cases of severe illness. The infection is responsible for 290,000 to 650,000 respiratory deaths each year, underscoring its substantial impact on public health systems worldwide. Significantly, 99% of influenza-related lower respiratory tract infection deaths among children under five occur in developing countries, highlighting stark inequalities in healthcare access and outcomes. Moreover, the WHO stated in September 2025 that every day, more than 1 million treatable sexually transmitted infections (STIs) are acquired in people aged 15 to 49 worldwide, with the majority of them asymptomatic. In 2022, an estimated 8 million adults aged 15 to 49 were infected with syphilis.

In addition, the market is expanding rapidly due to the increasing global burden of genetic diseases and the growing demand for rapid, accurate, and cost-effective testing. Traditional PCR and RT-PCR methods, although precise, require sophisticated equipment, trained personnel, and lengthy turnaround times, which limit their utility in resource-constrained and decentralized settings. CRISPR/Cas systems (Cas9, Cas12, and Cas13) offer unparalleled sensitivity, specificity, and programmability, enabling the detection of cancers and genetic variants with single-nucleotide resolution within an hour. Platforms like SHERLOCK and DETECTR have achieved attomolar sensitivity with simple lateral flow or fluorescence readouts, making them excellent candidates for point-of-care applications. CRISPR diagnostics, which combine molecular precision with operational simplicity and scalability, are reshaping the global diagnostics landscape and driving adoption in hospitals, clinics, and decentralized testing programs.

Moreover, the growing global urgency to address antimicrobial resistance (AMR), which has become one of the most important challenges in modern healthcare, is boosting the demand for the CRISPR-based POC diagnostics. Hospitals and healthcare systems worldwide are under increasing pressure to rapidly detect and contain antibiotic-resistant infections, thereby preventing costly outbreaks and improving patient outcomes. CRISPR-based diagnostic platforms offer a compelling value proposition by delivering fast, highly accurate, and easy-to-use testing solutions that reduce reliance on centralized laboratory facilities. These technologies enable clinicians to make early and targeted treatment decisions, minimizing the misuse of antibiotics and optimizing resource utilization. Their portability and scalability make them particularly attractive for deployment in resource-limited settings and point-of-care environments. By combining precision, speed, and accessibility, CRISPR diagnostics are revolutionizing the infectious disease diagnostics market and establishing new benchmarks for efficiency in clinical decision-making. For instance, in February 2025, Crisprbits (India) developed PathCrisp, a molecular diagnostic platform that uses CRISPR technology to detect antibiotic resistance in hospital-acquired infections. The technology is intended to allow early identification of AMR, a major worldwide health concern, particularly in intensive care units (ICUs).

Global CRISPR-based POC Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global CRISPR-based POC diagnostics market report based on product, technology, application, end-use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments/Devices
• Assay Kits and Reagents
• Software and Connectivity Platforms
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Cas9-Based
• Cas12-Based (DETECTR Technology)
• Cas13-Based (SHERLOCK Technology)
• Other Emerging Cas Systems
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Infectious Disease Diagnostics
• Genetic Disorder Testing
• Oncology Diagnostics
• Antimicrobial Resistance (AMR) Testing
• Other Applications
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals and Clinics
• Diagnostic Laboratories
• Homecare / At-Home Testing
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. CRISPR-based POC Diagnostics Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product
    • 1.1.1.2. Technology Segment
    • 1.1.1.3. Application Segment
    • 1.1.1.4. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. CRISPR-based POC Diagnostics Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Product
• 2.3. Technology Snapshot
• 2.4. Application Snapshot
• 2.5. End Use Snapshot
• 2.6. Competitive Landscape Snapshot

Chapter 3. CRISPR-based POC Diagnostics Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Decentralized and accessible diagnostics
  • 3.4.2. Rising global burden of infectious and genetic diseases
  • 3.4.3. Growing need to combat antimicrobial resistance (AMR)
• 3.5. Market Restraint Analysis
  • 3.5.1. Regulatory and clinical validation barriers
  • 3.5.2. Manufacturing scalability and cost constraints
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. CRISPR-based POC Diagnostics Market: Product Estimates & Trend Analysis

• 4.1. CRISPR-based POC Diagnostics Market: Product Movement Analysis
• 4.2. Instruments/Devices
  • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.3. Assay Kits and Reagents
  • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Software and Connectivity Platforms
  • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. CRISPR-based POC Diagnostics Market: Technology Estimates & Trend Analysis

• 5.1. CRISPR-based POC Diagnostics Market: Technology Movement Analysis
• 5.2. Cas9-Based
  • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.3. Cas12-Based (DETECTR Technology)
  • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Cas13-Based (SHERLOCK Technology)
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Other Emerging Cas Systems
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. CRISPR-based POC Diagnostics Market: Application Estimates & Trend Analysis

• 6.1. CRISPR-based POC Diagnostics Market: End Use Movement Analysis
• 6.2. Infectious Disease Diagnostics
  • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.3. Genetic Disorder Testing
  • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Oncology Diagnostics
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Antimicrobial Resistance (AMR) Testing
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Other Applications
  • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. CRISPR-based POC Diagnostics Market: End Use Estimates & Trend Analysis

• 7.1. CRISPR-based POC Diagnostics Market: End Use Movement Analysis
• 7.2. Hospitals and Clinics
  • 7.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.3. Diagnostic Laboratories
  • 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Homecare / At-Home Testing
  • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Others
  • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. CRISPR-based POC Diagnostics Market: Regional Business Analysis

• 8.1. Regional Market Snapshot
• 8.2. North America
  • 8.2.1. North America CRISPR-based POC Diagnostics Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. U.S. CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.2.2.2. Key Country Dynamics
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. Reimbursement Scenario
    • 8.2.2.5. Competitive Scenario
  • 8.2.3. Canada
    • 8.2.3.1. Canada CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.2.3.2. Key Country Dynamics
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Reimbursement Scenario
    • 8.2.3.5. Competitive Scenario
  • 8.2.4. Mexico
    • 8.2.4.1. Mexico CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.2.4.2. Key Country Dynamics
    • 8.2.4.3. Regulatory Framework
    • 8.2.4.4. Reimbursement Scenario
    • 8.2.4.5. Competitive Scenario
• 8.3. Europe
  • 8.3.1. Europe CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. UK CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.2.2. Key Country Dynamics
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Reimbursement Scenario
    • 8.3.2.5. Competitive Scenario
  • 8.3.3. Germany
    • 8.3.3.1. Germany CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.3.2. Key Country Dynamics
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Reimbursement Scenario
    • 8.3.3.5. Competitive Scenario
  • 8.3.4. Spain
    • 8.3.4.1. Spain CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.4.2. Key Country Dynamics
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Reimbursement Scenario
    • 8.3.4.5. Competitive Scenario
  • 8.3.5. France
    • 8.3.5.1. France CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.5.2. Key Country Dynamics
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Reimbursement Scenario
    • 8.3.5.5. Competitive Scenario
  • 8.3.6. Italy
    • 8.3.6.1. Italy CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.6.2. Key Country Dynamics
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Reimbursement Scenario
    • 8.3.6.5. Competitive Scenario
  • 8.3.7. Denmark
    • 8.3.7.1. Denmark CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.7.2. Key Country Dynamics
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Reimbursement Scenario
    • 8.3.7.5. Competitive Scenario
  • 8.3.8. Sweden
    • 8.3.8.1. Sweden CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.8.2. Key Country Dynamics
    • 8.3.8.3. Regulatory Framework
    • 8.3.8.4. Reimbursement Scenario
    • 8.3.8.5. Competitive Scenario
  • 8.3.9. Norway
    • 8.3.9.1. Norway CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.9.2. Key Country Dynamics
    • 8.3.9.3. Regulatory Framework
    • 8.3.9.4. Reimbursement Scenario
    • 8.3.9.5. Competitive Scenario
• 8.4. Asia Pacific
  • 8.4.1. Asia-Pacific CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Japan CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.2.2. Key Country Dynamics
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Scenario
    • 8.4.2.5. Competitive Scenario
  • 8.4.3. China
    • 8.4.3.1. China CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.3.2. Key Country Dynamics
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Scenario
    • 8.4.3.5. Competitive Scenario
  • 8.4.4. India
    • 8.4.4.1. India CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.4.2. Key Country Dynamics
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Scenario
    • 8.4.4.5. Competitive Scenario
  • 8.4.5. South Korea
    • 8.4.5.1. South Korea CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.5.2. Key Country Dynamics
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Reimbursement Scenario
    • 8.4.5.5. Competitive Scenario
  • 8.4.6. Thailand
    • 8.4.6.1. Thailand CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.6.2. Key Country Dynamics
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Reimbursement Scenario
    • 8.4.6.5. Competitive Scenario
  • 8.4.7. Australia
    • 8.4.7.1. Australia CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.7.2. Key Country Dynamics
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Reimbursement Scenario
    • 8.4.7.5. Competitive Scenario
• 8.5. Latin America
  • 8.5.1. Latin America CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Brazil CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.5.2.2. Key Country Dynamics
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Scenario
    • 8.5.2.5. Competitive Scenario
  • 8.5.3. Argentina
    • 8.5.3.1. Argentina CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.5.3.2. Key Country Dynamics
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Scenario
    • 8.5.3.5. Competitive Scenario
• 8.6. Middle East & Africa
  • 8.6.1. Middle East & Africa CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. South Africa CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.2.2. Key Country Dynamics
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Scenario
    • 8.6.2.5. Competitive Scenario
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Saudi Arabia CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.3.2. Key Country Dynamics
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Scenario
    • 8.6.3.5. Competitive Scenario
  • 8.6.4. UAE
    • 8.6.4.1. UAE CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.4.2. Key Country Dynamics
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Scenario
    • 8.6.4.5. Competitive Scenario
  • 8.6.5. Kuwait
    • 8.6.5.1. Kuwait CRISPR-based POC Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.5.2. Key Country Dynamics
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Scenario
    • 8.6.5.5. Competitive Scenario

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
  • 9.2.1. New Product Launch
  • 9.2.2. Partnerships
  • 9.2.3. Acquisition
  • 9.2.4. Collaboration
  • 9.2.5. Funding
• 9.3. Key Company Market Share Analysis, 2024
• 9.4. Company Heat Map Analysis
• 9.5. Company Profiles
  • 9.5.1. Mammoth Biosciences, Inc.
    • 9.5.1.1. Company Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. OraSure Technologies, Inc. (Sherlock Biosciences)
    • 9.5.2.1. Company Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Caspr Biotech
    • 9.5.3.1. Company Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. GenScript
    • 9.5.4.1. Company Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Integrated DNA Technologies, Inc.
    • 9.5.5.1. Company Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. Synthego
    • 9.5.6.1. Company Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Revvity Discovery Limited
    • 9.5.7.1. Company Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. Twist Bioscience
    • 9.5.8.1. Company Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Crisprbits
    • 9.5.9.1. Company Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Danaher Corporation (Cepheid)
    • 9.5.10.1. Company Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives